Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1404298

Primary Intestinal Diffuse Large B-cell Lymphoma: novel insights and clinical perception

Provisionally accepted
Xiaojun Chen Xiaojun Chen 1Jing Wang Jing Wang 2*Yanquan Liu Yanquan Liu 3Suxia Lin Suxia Lin 1*Jianzhen Shen Jianzhen Shen 4*Yue Yin Yue Yin 4*Yili Wang Yili Wang 2*
  • 1 Affiliated Hospital of Putian University, Putian, China
  • 2 First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province, China
  • 3 Dongguan First Hospital affiliated to Guangdong Medical University, Dongguan, China
  • 4 Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China

The final, formatted version of the article will be published soon.

    Background: Extranodal Non-Hodgkin lymphoma (NHL) is more prevalent in the gastrointestinal (GI) tract than in other sites. This study aimed to explore the clinical features and prognostic factors of primary intestinal diffuse large B-cell lymphoma (PI-DLBCL), in order to provide new references for basic research and clinical diagnosis and treatment of the rare extranodal malignant lymphoma.The clinical data of 88 patients with PI-DLBCL admitted to Fujian Medical University Union Hospital from June 2011 to June 2022 were retrospectively studied, the clinical and pathological features, diagnosis and treatment process and prognosis of PI-DLBCL were analyzed, and univariate and multivariate analysis of prognostic factors was carried out. The Kaplan-Meier method was used for survival analysis. Meanwhile, the latest literature from PubMed was retrieved to systematically discuss the research progress in the diagnosis and treatment of PI-DLBCL.Results: Among the 88 patients with PI-DLBCL included in this study, 60 cases were males (68.18%), 28 cases were females (31.82%), and 62 patients (70.45%) were complaining of abdominal pain, and the second most common clinical manifestation was changes in bowel habits in 16 (18.18%), with a median age of onset of 57 (17-82) years. The first-line treatment regimen was surgery combined with R-CHOP chemotherapy (56.82%). The median follow-up time was 72 (1-148) months, 51 (57.95%) of 88 patients with PI-DLBCL survived, 30 patients (34.09%) died, 7 patients (7.95%) were lost to follow-up, and the PFS rates of 1-year, 3-year and 5-year were 57.95%, 29.55% and 15.91%, and the OS rates of 1-year, 3-year and 5-year were 79.55%, 45.45% and 28.41%, respectively. The results of multivariate Cox analysis showed that Lugano stage may be an independent prognostic factor affecting OS and PFS in PI-DLBCL patients.PI-DLBCL is more common in middle-aged and elderly men, clinical manifestations lack specificity, first-line treatment is mainly surgery combined with standard chemotherapy regimens. The Lugano stage may be an independent prognostic factor affecting OS and PFS in PI-DLBCL patients.

    Keywords: Diffuse large B-cell lymphoma, Intestinal lymphoma, Extranodal lymphoma, Gastrointestinal Tract, prognosis

    Received: 20 Mar 2024; Accepted: 29 Jul 2024.

    Copyright: © 2024 Chen, Wang, Liu, Lin, Shen, Yin and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jing Wang, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province, China
    Suxia Lin, Affiliated Hospital of Putian University, Putian, China
    Jianzhen Shen, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China
    Yue Yin, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China
    Yili Wang, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.